Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Allison Upalawanna
Whitehawk Therapeutics
Study Director - Margaret C Dugan, MD
Whitehawk Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arkansas
Little Rock, Arkansas, United States
Michael Birrer, MDRecruiting - Ucla - Hematology/oncology Clinical Research Unit
Los Angeles, California, United States
Aaron Lisberg, MDNot, yet, recruiting - St. Francis Medical Center (osf Healthcare)
Peoria, Illinois, United States
Michelle Rowland, MDRecruiting - Start - Midwest
Grand Rapids, Michigan, United States
Manish SharmaRecruiting - Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey, United States
Miguel Gonzalez, MDRecruiting - Roswell Park Comprehensive Care Center
Buffalo, New York, United States
Bailey Fitzgerald, MDRecruiting - University Hospital - Cleveland Medical Center
Cleveland, Ohio, United States
Matthew MIrsky, MDRecruiting - Next Oncology - Austin
Austin, Texas, United States
Recruiting - Next - Oncology - Houston
Houston, Texas, United States
Jennifer Segar, MDRecruiting - Start - San Antonio
San Antonio, Texas, United States
Recruiting - Next Oncology - Virginia Cancer Specialists
Fairfax, Virginia, United States
Alexander Spira, MD, PhDRecruiting - Fred Hutchinson Cancer Center
Seattle, Washington, United States
Lei Deng, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Dec 2025
- Primary completion
- 31 Oct 2028
- Completion
- 31 Dec 2028
- Last update posted
- 5 Aug 2026
- Registered enrollment
- 226
- Registry id
- NCT07444814
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.